Regulator of G protein Signaling (RGS) proteins inhibit G protein-coupled receptor (GPCR) signaling, including the signals that arise from neurotransmitter release. We have shown that RGS12 loss diminishes locomotor responses of C57BL/6J mice to dopamine transporter (DAT)-targeting psychostimulants. This diminution resulted from a brain region-specific upregulation of DAT expression and function in RGS12-null mice. This effect on DAT prompted us to investigate whether the serotonin transporter (SERT) exhibits similar alterations upon RGS12 loss in C57BL/6J mice.
Aims:
Does RGS12 loss affect (a) hyperlocomotion to the preferentially SERT-targeting psychostimulant 3,4-methylenedioxymethamphetamine (MDMA), (b) SERT expression and function in relevant brain regions, and/or (c) serotonergically modulated behaviors?
Methods:
Open-field and spontaneous home-cage locomotor activities were quantified. 5-HT, 5-HIAA, and SERT levels in brain-region homogenates, as well as SERT expression and function in brain-region tissue preparations, were measured using appropriate biochemical assays. Serotonergically modulated behaviors were assessed using forced swim and tail suspension paradigms, elevated plus and elevated zero maze tests, and social interaction assays.
Results:
RGS12-null mice displayed no hyperlocomotion to 10 mg/kg MDMA. There were brain region-specific alterations in SERT expression and function associated with RGS12 loss. Drug-naïve RGS12-null mice displayed increases in both anxiety-like and anti-depressive-like behaviors.
Conclusion:
RGS12 is a critical modulator of serotonergic neurotransmission and serotonergically modulated behavior in mice; lack of hyperlocomotion to low dose MDMA in RGS12-null mice is related to an alteration of steady-state SERT expression and 5-HT uptake.
AnsorgeMSMorelliEGingrichJA (2008) Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci28: 199–207.
2.
AnsorgeMSZhouMLiraA, et al. (2004) Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science306: 879–881.
3.
BengelDMurphyDLAndrewsAM, et al. (1998) Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine (‘Ecstasy’) in serotonin transporter-deficient mice. Mol Pharmacol53: 649–655.
4.
BergerMGrayJARothBL (2009) The expanded biology of serotonin. Annu Rev Med60: 355–366.
5.
BeyALWangXYanH, et al. (2018) Brain region-specific disruption of Shank3 in mice reveals a dissociation for cortical and striatal circuits in autism-related behaviors. Transl Psychiatry8: 94.
6.
BlakelyRDDe FeliceLJHartzellHC (1994) Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol196: 263–281.
7.
BraidaDCapurroVZaniA, et al. (2009) Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol157: 844–853.
8.
ButkoMTSavasJNFriedmanB, et al. (2013) In vivo quantitative proteomics of somatosensory cortical synapses shows which protein levels are modulated by sensory deprivation. Proc Natl Acad Sci USA110: E726–735.
9.
CanADaoDTAradM, et al. (2012) The mouse forced swim test. J Vis Exp59: e3638.
10.
Carhart-HarrisRLNuttDJ (2017) Serotonin and brain function: A tale of two receptors. J Psychopharmacol31: 1091–1120.
11.
CastagneVMoserPRouxS, et al. (2011) Rodent models of depression: Forced swim and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci55: 8, 10A, 1–8, 10A, 14.
12.
CrespiDMenniniTGobbiM (1997) Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J Pharmacol121: 1735–1743.
13.
DaubertEACondronBG (2010) Serotonin: A regulator of neuronal morphology and circuitry. Trends Neurosci33: 424–434.
14.
DenerisEGasparP (2018) Serotonin neuron development: Shaping molecular and structural identities. Wiley Interdiscip Rev Dev Biol7: e301.
15.
DiazSLDolySNarboux-NemeN, et al. (2012) 5-HT(2B) receptors are required for serotonin-selective antidepressant actions. Mol Psychiatry17: 154–163.
16.
DohnMRKookerCGBastaracheL, et al. (2017) The gain-of-function integrin beta3 Pro33 variant alters the serotonin system in the mouse brain. J Neurosci37: 11271–11284.
17.
DolySValjentESetolaV, et al. (2008) Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci28: 2933–2940.
18.
FukuiMRodriguizRMZhouJ, et al. (2007) Vmat2 heterozygous mutant mice display a depressive-like phenotype. J Neurosci27: 10520–10529.
19.
GrossJDKaskiSWSchmidtKT, et al. (2019) Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior. Neuropsychopharmacology44: 1728–1741.
20.
GrossJDKaskiSWSchroerAB, et al. (2018) Regulator of G protein signaling-12 modulates the dopamine transporter in ventral striatum and locomotor responses to psychostimulants. J Psychopharmacol32: 191–203.
21.
HaginoYTakamatsuYYamamotoH, et al. (2011) Effects of MDMA on extracellular dopamine and serotonin levels in mice lacking dopamine and/or serotonin transporters. Curr Neuropharmacol9: 91–95.
22.
HanDDGuHH (2006) Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol6: 6.
23.
HendricksTFrancisNFyodorovD, et al. (1999) The ETS domain factor Pet-1 is an early and precise marker of central serotonin neurons and interacts with a conserved element in serotonergic genes. J Neurosci19: 10348–10356.
24.
HigginsGABradburyAJJonesBJ, et al. (1988) Behavioural and biochemical consequences following activation of 5HT1-like and GABA receptors in the dorsal raphe nucleus of the rat. Neuropharmacology27: 993–1001.
25.
HilberBScholzePDorostkarMM, et al. (2005) Serotonin-transporter mediated efflux: A pharmacological analysis of amphetamines and non-amphetamines. Neuropharmacology49: 811–819.
26.
HolmesAMurphyDLCrawleyJN (2003a) Abnormal behavioral phenotypes of serotonin transporter knockout mice: Parallels with human anxiety and depression. Biol Psychiatry54: 953–959.
27.
HolmesAYangRJLeschKP, et al. (2003b) Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology28: 2077–2088.
28.
HolmesAYangRJMurphyDL, et al. (2002) Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology27: 914–923.
29.
IversenL (2000) Neurotransmitter transporters: Fruitful targets for CNS drug discovery. Mol Psychiatry5: 357–362.
30.
JenningsKALoderMKShewardWJ, et al. (2006) Increased expression of the 5-HT transporter confers a low-anxiety phenotype linked to decreased 5-HT transmission. J Neurosci26: 8955–8964.
31.
KalueffAVFoxMAGallagherPS, et al. (2007) Hypolocomotion, anxiety and serotonin syndrome-like behavior contribute to the complex phenotype of serotonin transporter knockout mice. Genes Brain Behav6: 389–400.
32.
KinseySGBaileyMTSheridanJF, et al. (2007) Repeated social defeat causes increased anxiety-like behavior and alters splenocyte function in C57BL/6 and CD-1 mice. Brain Behav Immun21: 458–466.
33.
KiyasovaVFernandezSPLaineJ, et al. (2011) A genetically defined morphologically and functionally unique subset of 5-HT neurons in the mouse raphe nuclei. J Neurosci31: 2756–2768.
34.
KochSGallowayMP (1997) MDMA induced dopamine release in vivo: Role of endogenous serotonin. J Neural Transm (Vienna)104: 135–146.
35.
KulkarniSKSinghKBishnoiM (2007) Elevated zero maze: A paradigm to evaluate antianxiety effects of drugs. Methods Find Exp Clin Pharmacol29: 343–348.
36.
LiechtiMEBaumannCGammaA, et al. (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology22: 513–521.
37.
LineSJBarkusCCoyleC, et al. (2011) Opposing alterations in anxiety and species-typical behaviours in serotonin transporter overexpressor and knockout mice. Eur Neuropsychopharmacol21: 108–116.
38.
LiraAZhouMCastanonN, et al. (2003) Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol Psychiatry54: 960–971.
39.
LivakKJSchmittgenTD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods25: 402–408.
40.
Martin-McCaffreyLHainsMDPritchardGA, et al. (2005) Differential expression of regulator of G-protein signaling R12 subfamily members during mouse development. Dev Dyn234: 438–444.
41.
MayorgaAJLuckiI (2001) Limitations on the use of the C57BL/6 mouse in the tail suspension test. Psychopharmacology (Berl)155: 110–112.
42.
MeltzerHY (1990) Role of serotonin in depression. Ann NY Acad Sci600: 486–499; discussion 499–500.
43.
MithoeferMCWagnerMTMithoeferAT, et al. (2011) The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. J Psychopharmacol25: 439–452.
44.
MosienkoVBertBBeisD, et al. (2012) Exaggerated aggression and decreased anxiety in mice deficient in brain serotonin. Transl Psychiatry2: e122.
45.
MuzerelleAScotto-LomasseseSBernardJF, et al. (2016) Conditional anterograde tracing reveals distinct targeting of individual serotonin cell groups (B5-B9) to the forebrain and brainstem. Brain Struct Funct221: 535–561.
46.
NordquistNOrelandL (2010) Serotonin, genetic variability, behaviour, and psychiatric disorders–a review. Ups J Med Sci115: 2–10.
47.
NuttDJ (2002) The neuropharmacology of serotonin and noradrenaline in depression. Int Clin Psychopharmacol17(Suppl 1): S1–S12.
48.
OehenPTraberRWidmerV, et al. (2013) A randomized, controlled pilot study of MDMA (+/- 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol27: 40–52.
49.
OkatyBWCommonsKGDymeckiSM (2019) Embracing diversity in the 5-HT neuronal system. Nat Rev Neurosci20: 397–424.
50.
OliverKHDuvernayMTHammHE, et al. (2016) Loss of serotonin transporter function alters ADP-mediated glycoprotein alphaIIbbeta3 activation through dysregulation of the 5-HT2A receptor. J Biol Chem291: 20210–20219.
51.
OwensMJNemeroffCB (1994) Role of serotonin in the pathophysiology of depression: Focus on the serotonin transporter. Clin Chem40: 288–295.
52.
ParrottAC (2002) Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav71: 837–844.
53.
ParrottAC (2004) Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl)173: 234–241.
54.
PrattLABrodyDJGuQ (2017) Antidepressant use among persons aged 12 and over: United States,2011–2014. NCHS Data Brief. 1–8.
RothmanRBBaumannMHDerschCM, et al. (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse39: 32–41.
57.
RudnickGWallSC (1992) The molecular mechanism of ‘ecstasy’ [3,4-methylenedioxy-methamphetamine (MDMA)]: Serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA89: 1817–1821.
58.
SandtnerWStocknerTHasenhuetlPS, et al. (2016) Binding mode selection determines the action of ecstasy homologs at monoamine transporters. Mol Pharmacol89: 165–175.
59.
SchindlerAGMessingerDISmithJS, et al. (2012) Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake. J Neurosci32: 17582–17596.
60.
ShepherdJKGrewalSSFletcherA, et al. (1994) Behavioural and pharmacological characterisation of the elevated ‘zero-maze’ as an animal model of anxiety. Psychopharmacology (Berl)116: 56–64.
61.
SialanaFJWangALFazariB, et al. (2018) Quantitative proteomics of synaptosomal fractions in a rat overexpressing human DISC1 gene indicates profound synaptic dysregulation in the dorsal striatum. Front Mol Neurosci11: 26.
62.
SnowBEAntonioLSuggsS, et al. (1997) Molecular cloning and expression analysis of rat Rgs12 and Rgs14. Biochem Biophys Res Commun233: 770–777.
63.
SnowBEHallRAKruminsAM, et al. (1998) GTPase activating specificity of RGS12 and binding specificity of an alternatively spliced PDZ (PSD-95/Dlg/ZO-1) domain. J Biol Chem273: 17749–17755.
64.
SoundararajanMWillardFSKimpleAJ, et al. (2008) Structural diversity in the RGS domain and its interaction with heterotrimeric G protein alpha-subunits. Proc Natl Acad Sci USA105: 6457–6462.
65.
SpanosLJYamamotoBK (1989) Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol Biochem Behav32: 835–840.
66.
SteruLChermatRThierryB, et al. (1985) The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology (Berl)85: 367–370.
67.
SundaramurthySAnnamalaiBSamuvelDJ, et al. (2017) Modulation of serotonin transporter function by kappa-opioid receptor ligands. Neuropharmacology113: 281–292.
68.
SuriDTeixeiraCMCagliostroMK, et al. (2015) Monoamine-sensitive developmental periods impacting adult emotional and cognitive behaviors. Neuropsychopharmacology40: 88–112.
69.
TeissierAChemiakineAInbarB, et al. (2015) Activity of raphe serotonergic neurons controls emotional behaviors. Cell Rep13: 1965–1976.
70.
UhlGRJohnsonPS (1994) Neurotransmitter transporters: Three important gene families for neuronal function. J Exp Biol196: 229–236.
71.
WalfAAFryeCA (2007) The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc2: 322–328.
72.
WillardMDWillardFSLiX, et al. (2007) Selective role for RGS12 as a Ras/Raf/MEK scaffold in nerve growth factor-mediated differentiation. EMBO J26: 2029–2040.
73.
YadavPNAbbasAIFarrellMS, et al. (2011) The presynaptic component of the serotonergic system is required for clozapine’s efficacy. Neuropsychopharmacology36: 638–651.
74.
YeRCarneiroAMAireyD, et al. (2014) Evaluation of heritable determinants of blood and brain serotonin homeostasis using recombinant inbred mice. Genes Brain Behav13: 247–260.
75.
YeRQuinlanMAIwamotoH, et al. (2015) Physical interactions and functional relationships of neuroligin 2 and midbrain serotonin transporters. Front Synaptic Neurosci7: 20.
76.
YuQTeixeiraCMMahadeviaD, et al. (2014) Dopamine and serotonin signaling during two sensitive developmental periods differentially impact adult aggressive and affective behaviors in mice. Mol Psychiatry19: 688–698.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
